Natasha Lucas

Natasha Lucas

Auto-generated profile, based on publicly available information

Natasha Lucas

Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RPRebecca Poulos
Rebecca Poulos
PHPeter Hains
Peter Hains
RSRohan Shah
Rohan Shah
NLNatasha Lucas
Natasha Lucas
DXDylan Xavier
Dylan Xavier
QZQing Zhong
Qing Zhong
Reproducible research is the bedrock of experimental science. To enable the deployment of large-scale proteomics, we assess the reproducibility of mass spectrometry (MS) over time and across instruments and develop computational methods for improving quantitative accuracy. We perform 1560 data independent acquisition (DIA)-MS runs of eight samples containing known proportions of ovarian and prostate cancer tissue and yeast, or control HEK293T cells. Replicates are run on six mass spectrometers operating continuously with varying maintenance schedules over four months, interspersed with ~5000 other runs. We utilise negative controls and replicates to remove unwanted variation and enhance biological signal, outperforming existing methods. We also design a method for reducing missing values. Integrating these computational modules into a pipeline (ProNorM), we mitigate variation among instruments over time and accurately predict tissue proportions. We demonstrate how to improve the quantitative analysis of large-scale DIA-MS data, providing a pathway toward clinical proteomics.

27 March 2009 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
ITI. Thompson
I. Thompson
GWG. Williams
G. Williams
BCB. Caldwell
B. Caldwell
SAS. Aldington
S. Aldington
SDS. Dickson
S. Dickson
RBR. Beasley
R. Beasley
The objective of this study was to determine the clinical effects of party pills containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) when taken alone and in combination with alcohol. The study was a randomised, double-blind, placebo-controlled trial conducted in a hospital-based clinic in Wellington, New Zealand. Thirty-five volunteers who had previously used party pills containing BZP were included in this trial. Participants received one of the following four treatments: 300 mg/74 mg BZP/TFMPP and placebo, 300 mg/74 mg BZP/TFMPP and 57.6 g (6 units) alcohol, placebo and 57.6 g (6 units) alcohol and double placebo. The primary outcome variable was a measure of driving performance, the standard deviation of lateral position (SDLP) measured at 6.5 h. Secondary measures included adverse events, cardiovascular effects, psychological function and delayed effects on sleep. The study was stopped early, after 35 of the planned 64 subjects had undertaken testing, because of severe adverse events that occurred in four of 10 BZP/TFMPP-only subjects, three of seven combined BZP/TFMPP and alcohol subjects, none of the 6 placebo subjects, and none of the 12 alcohol-only subjects. The overall rate of severe adverse events (defined as causing considerable interference with usual activity and/or rated by subject as severe) in those receiving BZP/TFMPP was seven of 17 (41.2%, 95% CI 18.4—67.1). The severe events included agitation, anxiety, hallucinations, vomiting, insomnia and migraine. BZP/TFMPP significantly improved the driving performance, decreasing SDLP at −4.2 cm (95% CI −6.8 to −1.6, P = 0.002). The effect of alcohol was to increase SDLP: 2.3 cm (95% CI −0.3 to 4.9, P = 0.08). BZP/TFMPP also resulted in increased heart rate and blood pressure and in difficulty in getting to sleep. BZP/TFMPP alone or with alcohol carries a significant risk of severe adverse events when taken in similar doses to those recommended by manufacturers.

28 November 2018 in Journal of Proteome Research
Verified
Journal Article
Closed access
NLNatasha Lucas
Natasha Lucas
ARAndrew B. Robinson
Andrew B. Robinson
MEMaiken Marcker Espersen
Maiken Marcker Espersen
SMSadia Mahboob
Sadia Mahboob
DXDylan Xavier
Dylan Xavier
PRPhillip J. Robinson
Phillip J. Robinson

4 December 2023 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
QZQing Zhong
Qing Zhong
RSRui Sun
Rui Sun
AAAdel T Aref
Adel T Aref
ZNZainab Noor
Zainab Noor
AAAsim Anees
Asim Anees
PWPeter Wild
Peter Wild
Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in the Gleason grade group (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or overtreatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign sample runs from 278 patients. Three proteins (F5, TMEM126B, and EARS2) were identified as candidate biomarkers in patients with biochemical recurrence. Multivariate Cox regression yielded 18 proteins, from which a risk score was constructed to dichotomize prostate cancer patients into low- and high-risk groups. This 18-protein signature is prognostic for the risk of biochemical recurrence and completely independent of the intermediate GG. Our results suggest that markers generated by computational proteomic profiling have the potential for clinical applications including integration into prostate cancer management.

9 June 2025 in Cancer Discovery
Verified
Journal Article
Open access
ZCZhaoxiang Cai
Zhaoxiang Cai
EBEmma Boys
Emma Boys
ZNZainab Noor
Zainab Noor
AAAdel T. Aref
Adel T. Aref
DXDylan Xavier
Dylan Xavier
RRRoger Reddel
Roger Reddel
Artificial intelligence applications in biomedicine face major challenges from data privacy requirements. To address this issue for clinically annotated tissue proteomic data, we developed a federated deep learning approach (ProCanFDL), training local models on simulated sites containing data from a pan-cancer cohort (n = 1,260) and 29 cohorts held behind private firewalls (n = 6,265), representing 19,930 replicate data-independent acquisition mass spectrometry runs. Local parameter updates were aggregated to build the global model, achieving a 43% performance gain on the hold-out test set (n = 625) in 14 cancer subtyping tasks compared with local models and matching centralized model performance. The approach’s generalizability was demonstrated by retraining the global model with data from two external, data-independent acquisition mass spectrometry cohorts (n = 55) and eight acquired by tandem mass tag proteomics (n = 832). ProCanFDL presents a solution for internationally collaborative machine learning initiatives using proteomic data, for example, for discovering predictive biomarkers or treatment targets while maintaining data privacy. Significance: A federated deep learning approach applied to human proteomic data, acquired using two distinct proteomic technologies from 40 tumor cohorts across eight countries, enabled accurate cancer histopathologic subtyping while preserving data privacy. This approach will enable the privacy-compliant development of large-scale proteomic artificial intelligence models, including foundation models, across institutions globally.

1 March 2024 in Analytical Chemistry
Verified
Journal Article
Closed access
DXDylan Xavier
Dylan Xavier
NLNatasha Lucas
Natasha Lucas
SWSteven G. Williams
Steven G. Williams
JKJennifer M. S. Koh
Jennifer M. S. Koh
KAKeith Ashman
Keith Ashman
PRPhillip J. Robinson
Phillip J. Robinson